A potent anti-CD70 antibody-drug conjugate combining a dimeric pyrrolobenzodiazepine drug with site-specific conjugation technology

Bioconjugate Chemistry

Volumn 24, Issue 7, 2013, Pages 1256-1263

  Jeffrey, Scott C ^a   Burke, Patrick J ^a   Lyon, Robert P ^a   Meyer, David W ^a   Sussman, Django ^a   Anderson, Martha ^a   Hunter, Joshua H ^a   Leiske, Chris I ^a   Miyamoto, Jamie B ^a   Nicholas, Nicole D ^a   Okeley, Nicole M ^a   Sanderson, Russell J ^a   Stone, Ivan J ^a   Zeng, Weiping ^a   Gregson, Stephen J ^b   Masterson, Luke ^b   Tiberghien, Arnaud C ^b   Howard, Philip W ^b   Thurston, David E ^c   Law, Che Leung ^a   Senter, Peter D ^a   more..

^a SEATTLE GENETICS INC   (United States)

^b ASTRAZENECA   (United Kingdom)

^c KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODIES; CELL CULTURE; CYTOTOXICITY;

ALANINE DIPEPTIDES; ANTIBODY-DRUG CONJUGATES; CROSS LINKING; CYTOTOXIC; HEAVY CHAIN; NON-HODGKIN LYMPHOMA; PYRROLOBENZODIAZEPINE; RENAL CELL CARCINOMA; SITE-SPECIFIC; SPECIFIC CONJUGATIONS;

AMINO ACIDS;

ANTINEOPLASTIC AGENT; CD70 ANTIGEN; CYSTEINE; H1F6 MONOCLONAL ANTIBODY PYRROLOBENZODIAZEPINE CONJUGATE; MONOCLONAL ANTIBODY; N ETHYLMALEIMIDE; PYRROLOBENZODIAZEPINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW TOXICITY; CONTROLLED STUDY; CYTOTOXICITY; DNA CROSS LINKING; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CONJUGATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; IC 50; IN VITRO STUDY; KIDNEY CARCINOMA; MOUSE; NONHODGKIN LYMPHOMA; NONHUMAN; PROTEIN EXPRESSION; TUMOR XENOGRAFT;

EID: 84880380678     PISSN: 10431802     EISSN: 15204812     Source Type: Journal    
DOI: 10.1021/bc400217g     Document Type: Article

References (40)

1. Senter, P. D. and Sievers, E. L. (2012) The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma Nat. Biotechnol. 30, 631-7
2. Senter, P. D. (2009) Potent antibody drug conjugates for cancer therapy Curr. Opin. Chem. Biol. 13, 235-44
3. Sievers, E. L. and Senter, P. D. (2013) Antibody-drug conjugates in cancer therapy Annu. Rev. Med. 64, 15-29
4. Burke, P. J., Senter, P. D., Meyer, D. W., Miyamoto, J. B., Anderson, M., Toki, B. E., Manikumar, G., Wani, M. C., Kroll, D. J., and Jeffrey, S. C. (2009) Design, synthesis, and biological evaluation of antibody-drug conjugates comprised of potent camptothecin analogues Bioconjugate Chem. 20, 1242-50
5. Burke, P. J., Toki, B. E., Meyer, D. W., Miyamoto, J. B., Kissler, K. M., Anderson, M., Senter, P. D., and Jeffrey, S. C. (2009) Novel immunoconjugates comprised of streptonigrin and 17-amino-geldanamycin attached via a dipeptide-p-aminobenzyl-amine linker system Bioorg. Med. Chem. Lett. 19, 2650-3
6. Jeffrey, S. C., Nguyen, M. T., Andreyka, J. B., Meyer, D. L., Doronina, S. O., and Senter, P. D. (2006) Dipeptide-based highly potent doxorubicin antibody conjugates Bioorg. Med. Chem. Lett. 16, 358-62
7. Jeffrey, S. C., Torgov, M. Y., Andreyka, J. B., Boddington, L., Cerveny, C. G., Denny, W. A., Gordon, K. A., Gustin, D., Haugen, J., Kline, T., Nguyen, M. T., and Senter, P. D. (2005) Design, synthesis, and in vitro evaluation of dipeptide-based antibody minor groove binder conjugates J. Med. Chem. 48, 1344-58
8. Doronina, S. O., Bovee, T. D., Meyer, D. W., Miyamoto, J. B., Anderson, M. E., Morris-Tilden, C. A., and Senter, P. D. (2008) Novel peptide linkers for highly potent antibody-auristatin conjugate Bioconjugate Chem. 19, 1960-3
9. Jeffrey, S. C., Andreyka, J. B., Bernhardt, S. X., Kissler, K. M., Kline, T., Lenox, J. S., Moser, R. F., Nguyen, M. T., Okeley, N. M., Stone, I. J., Zhang, X., and Senter, P. D. (2006) Development and properties of beta-glucuronide linkers for monoclonal antibody-drug conjugates Bioconjugate Chem. 17, 831-40
10. Hamblett, K. J., Senter, P. D., Chace, D. F., Sun, M. M., Lenox, J., Cerveny, C. G., Kissler, K. M., Bernhardt, S. X., Kopcha, A. K., Zabinski, R. F., Meyer, D. L., and Francisco, J. A. (2004) Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate Clin. Cancer. Res. 10, 7063-70
11. Doronina, S. O., Toki, B. E., Torgov, M. Y., Mendelsohn, B. A., Cerveny, C. G., Chace, D. F., DeBlanc, R. L., Gearing, R. P., Bovee, T. D., Siegall, C. B., Francisco, J. A., Wahl, A. F., Meyer, D. L., and Senter, P. D. (2003) Development of potent monoclonal antibody auristatin conjugates for cancer therapy Nat. Biotechnol. 21, 778-84
12. Alley, S. C., Benjamin, D. R., Jeffrey, S. C., Okeley, N. M., Meyer, D. L., Sanderson, R. J., and Senter, P. D. (2008) Contribution of linker stability to the activities of anticancer immunoconjugates Bioconjugate Chem. 19, 759-65
13. Doronina, S. O., Mendelsohn, B. A., Bovee, T. D., Cerveny, C. G., Alley, S. C., Meyer, D. L., Oflazoglu, E., Toki, B. E., Sanderson, R. J., Zabinski, R. F., Wahl, A. F., and Senter, P. D. (2006) Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity Bioconjugate Chem. 17, 114-24
14. Junutula, J. R., Flagella, K. M., Graham, R. A., Parsons, K. L., Ha, E., Raab, H., Bhakta, S., Nguyen, T., Dugger, D. L., Li, G., Mai, E., Lewis Phillips, G. D., Hiraragi, H., Fuji, R. N., Tibbitts, J., Vandlen, R., Spencer, S. D., Scheller, R. H., Polakis, P., and Sliwkowski, M. X. (2010) Engineered thio-trastuzumab-DM1 conjugate with an improved therapeutic index to target human epidermal growth factor receptor 2-positive breast cancer Clin. Cancer. Res. 16, 4769-78
15. Grewal, I. S. (2008) CD70 as a therapeutic target in human malignancies Expert Opin. Ther. Targets 12, 341-51
16. Boursalian, T. E., McEarchern, J. A., Law, C. L., and Grewal, I. S. (2009) Targeting CD70 for human therapeutic use Adv. Exp. Med. Biol. 647, 108-19
17. Hartley, J. A., Hamaguchi, A., Coffils, M., Martin, C. R., Suggitt, M., Chen, Z., Gregson, S. J., Masterson, L. A., Tiberghien, A. C., Hartley, J. M., Pepper, C., Lin, T. T., Fegan, C., Thurston, D. E., and Howard, P. W. (2010) SG2285, a novel C2-aryl-substituted pyrrolobenzodiazepine dimer prodrug that cross-links DNA and exerts highly potent antitumor activity Cancer Res. 70, 6849-58
18. Howard, P. W., Chen, Z., Gregson, S. J., Masterson, L. A., Tiberghien, A. C., Cooper, N., Fang, M., Coffils, M. J., Klee, S., Hartley, J. A., and Thurston, D. E. (2009) Synthesis of a novel C2/C2′-aryl-substituted pyrrolo[2,1-c][1,4]benzodiazepine dimer prodrug with improved water solubility and reduced DNA reaction rate Bioorg. Med. Chem. Lett. 19, 6463-6
19. Sutherland, M. S., Walter, R. B., Jeffrey, S. C., Burke, P. J., Yu, C., Stone, I., Ryan, M. C., Sussman, D., Zeng, W., Harrington, K. H., Klussman, K., Westendorf, L., Meyer, D., Bernstein, I. D., Senter, P. D., Drachman, J. G., and McEarchern, J. A. (In Press) SGN-CD33A: A novel CD33-targeting antibody-drug conjugate utilizing a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML.
20. Howard, P. W., Gregson, S. J., and Masterson, L. (2010) Unsymmetrical pyrrolobenzodiazepine-dimers for treatment of proliferative diseases. WO2010/43880 A1.
21. Rahman, K. M., Thompson, A. S., James, C. H., Narayanaswamy, M., and Thurston, D. E. (2009) The pyrrolobenzodiazepine dimer SJG-136 forms sequence-dependent intrastrand DNA cross-links and monoalkylated adducts in addition to interstrand cross-links J. Am. Chem. Soc. 131, 13756-66
22. Rahman, K. M., H., V., James, C. H., Howard, P. W., and Thurston, D. E. (2010) DNA sequence preference and adduct orientation of pyrrolo[2,1-c][1,4] benzodiazepine antitumor agents ACS Med. Chem. Lett. 1, 427-32
23. Rahman, K. M., James, C. H., and Thurston, D. E. (2011) Effect of base sequence on the DNA cross-linking properties of pyrrolobenzodiazepine (PBD) dimers Nucleic Acids Res. 39, 5800-12
24. Antonow, D., Kaliszczak, M., Kang, G. D., Coffils, M., Tiberghien, A. C., Cooper, N., Barata, T., Heidelberger, S., James, C. H., Zloh, M., Jenkins, T. C., Reszka, A. P., Neidle, S., Guichard, S. M., Jodrell, D. I., Hartley, J. A., Howard, P. W., and Thurston, D. E. (2010) Structure-activity relationships of monomeric C2-aryl pyrrolo[2,1-c][1,4]benzodiazepine (PBD) antitumor agents J. Med. Chem. 53, 2927-41
25. Law, C. L., Gordon, K. A., Toki, B. E., Yamane, A. K., Hering, M. A., Cerveny, C. G., Petroziello, J. M., Ryan, M. C., Smith, L., Simon, R., Sauter, G., Oflazoglu, E., Doronina, S. O., Meyer, D. L., Francisco, J. A., Carter, P., Senter, P. D., Copland, J. A., Wood, C. G., and Wahl, A. F. (2006) Lymphocyte activation antigen CD70 expressed by renal cell carcinoma is a potential therapeutic target for anti-CD70 antibody-drug conjugates Cancer Res. 66, 2328-37
26. McEarchern, J. A., Smith, L. M., McDonagh, C. F., Klussman, K., Gordon, K. A., Morris-Tilden, C. A., Duniho, S., Ryan, M., Boursalian, T. E., Carter, P. J., Grewal, I. S., and Law, C. L. (2008) Preclinical characterization of SGN-70, a humanized antibody directed against CD70 Clin. Cancer. Res. 14, 7763-72
27. Sun, M. M., Beam, K. S., Cerveny, C. G., Hamblett, K. J., Blackmore, R. S., Torgov, M. Y., Handley, F. G., Ihle, N. C., Senter, P. D., and Alley, S. C. (2005) Reduction-alkylation strategies for the modification of specific monoclonal antibody disulfides Bioconjugate Chem. 16, 1282-90
28. Fraczkiewicz, R. and Braun, W. (1998) Exact and efficient analytical calculation of the accessible surface areas and their gradients for macromolecules J. Comput. Chem. 19, 319-33
29. Lamy, T., Drenou, B., Grulois, I., Fardel, O., Jacquelinet, C., Goasguen, J., Dauriac, C., Amiot, L., Bernard, M., and Fauchet, R. (1995) Multi-drug resistance (MDR) activity in acute leukemia determined by rhodamine 123 efflux assay Leukemia 9, 1549-55
30. Kawabata, M., Kobayashi, H., Mori, S., Sekiguchi, S., and Takemura, Y. (1997) Flow cytometric analysis of P-glycoprotein function by rhodamine 123 dye-efflux assay in human leukemia cells Rinsho Byori 45, 891-8
31. Jawad, M., Seedhouse, C., Mony, U., Grundy, M., Russell, N. H., and Pallis, M. (2010) Analysis of factors that affect in vitro chemosensitivity of leukaemic stem and progenitor cells to gemtuzumab ozogamicin (Mylotarg) in acute myeloid leukaemia Leukemia 24, 74-80
32. Aird, R. E., Thomson, M., Macpherson, J. S., Thurston, D. E., Jodrell, D. I., and Guichard, S. M. (2008) ABCB1 genetic polymorphism influences the pharmacology of the new pyrrolobenzodiazepine derivative SJG-136 Pharmacogenomics J. 8, 289-96
33. Guichard, S. M., Macpherson, J. S., Thurston, D. E., and Jodrell, D. I. (2005) Influence of P-glycoprotein expression on in vitro cytotoxicity and in vivo antitumour activity of the novel pyrrolobenzodiazepine dimer SJG-136 Eur. J. Cancer 41, 1811-8
34. Yu, D. S., Chang, S. Y., and Ma, C. P. (1998) The expression of MDR-1-related GP-170 and its correlation with anthracycline resistance in renal cell carcinoma cell lines and multidrug-resistant sublines Br. J. Urol. 82, 544-7
35. Walsh, N., Larkin, A., Kennedy, S., Connolly, L., Ballot, J., Ooi, W., Gullo, G., Crown, J., Clynes, M., and O'Driscoll, L. (2009) Expression of multidrug resistance markers ABCB1 (MDR-1/P-gp) and ABCC1 (MRP-1) in renal cell carcinoma BMC Urol. 9, 6
36. Lyon, R. P., Meyer, D. L., Setter, J. R., and Senter, P. D. (2012) Conjugation of anticancer drugs through endogenous monoclonal antibody cysteine residues Methods Enzymol. 502, 123-38
37. Fleming, M. S., Zhang, W., Lambert, J. M., and Amphlett, G. (2005) A reversed-phase high-performance liquid chromatography method for analysis of monoclonal antibody-maytansinoid immunoconjugates Anal. Biochem. 340, 272-8
38. Shen, B. Q., Xu, K., Liu, L., Raab, H., Bhakta, S., Kenrick, M., Parsons-Reponte, K. L., Tien, J., Yu, S. F., Mai, E., Li, D., Tibbitts, J., Baudys, J., Saad, O. M., Scales, S. J., McDonald, P. J., Hass, P. E., Eigenbrot, C., Nguyen, T., Solis, W. A., Fuji, R. N., Flagella, K. M., Patel, D., Spencer, S. D., Khawli, L. A., Ebens, A., Wong, W. L., Vandlen, R., Kaur, S., Sliwkowski, M. X., Scheller, R. H., Polakis, P., and Junutula, J. R. (2012) Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates Nat. Biotechnol. 30, 184-9
39. Junutula, J. R., Raab, H., Clark, S., Bhakta, S., Leipold, D. D., Weir, S., Chen, Y., Simpson, M., Tsai, S. P., Dennis, M. S., Lu, Y., Meng, Y. G., Ng, C., Yang, J., Lee, C. C., Duenas, E., Gorrell, J., Katta, V., Kim, A., McDorman, K., Flagella, K., Venook, R., Ross, S., Spencer, S. D., Lee Wong, W., Lowman, H. B., Vandlen, R., Sliwkowski, M. X., Scheller, R. H., Polakis, P., and Mallet, W. (2008) Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index Nat. Biotechnol. 26, 925-32
40. Tassone, P., Gozzini, A., Goldmacher, V., Shammas, M. A., Whiteman, K. R., Carrasco, D. R., Li, C., Allam, C. K., Venuta, S., Anderson, K. C., and Munshi, N. C. (2004) In vitro and in vivo activity of the maytansinoid immunoconjugate huN901-N2′-deacetyl-N2′-(3-mercapto-1-oxopropyl)- maytansine against CD56+ multiple myeloma cells Cancer Res. 64, 4629-36